RxDoctor Payments Data

Jedd Moore, NP

Nurse Practitioner · Boise, IDNPI 1902380371

Payments from drug & device makers

$1,937in general payments, 2019–2025

Across 53 payments — averaging $36.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$337
  • Amgen$278
  • GSK$229
  • Novo Nordisk$179
  • Bayer$159
  • Idorsia Pharmaceuticals US Inc$149
  • plus $607 from 14 others

What the payments were for

  • Food & beverage$1,937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,937 in reported general payments places this provider in the 85th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$12,282
Medicare patients
50
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$31,981
OzempicSemaglutide16$20,747
FarxigaDapagliflozin Propanediol18$18,086
JardianceEmpagliflozin12$14,911
BelsomraSuvorexant12$5,213
Levothyroxine Sodium38$508
Sertraline Hcl15$452
Atorvastatin Calcium26$442
Omeprazole30$299
Lisinopril44$264
Losartan Potassium27$252
Rosuvastatin Calcium31$170
Metoprolol Succinate11$156
Metformin Hcl12$90
Amlodipine Besylate15$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$337$31,98130 claims
Novo NordiskOzempic$179$20,74716 claims
AstraZenecaFarxiga$28$18,08618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →